Mayne Pharma Group (ASX:MYX): Specialty Pharmaceuticals and FY2026 Business Update

Sonal Goyal

15 September 2026 03:28 AM AEST

Mayne Pharma Group (ASX:MYX): Specialty Pharmaceuticals and FY2026 Business Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mayne Pharma Group (ASX:MYX) is a specialty pharmaceutical company focused on branded medicines.
The company operates across Women's Health, Dermatology and International segments.
FY2026 results included a statutory profit after a loss in the prior year.
Mayne Pharma continues expanding its commercial platforms and product portfolio.
Product demand, market access and operational execution remain key areas to monitor.

Mayne Pharma Group (ASX:MYX) is an Australian specialty pharmaceutical company focused on commercialising branded medicines across healthcare markets. The company operates through multiple therapeutic areas, including Women's Health and Dermatology, while continuing to develop its commercial capabilities.

Company Overview

Mayne Pharma Group is an ASX-listed specialty pharmaceutical company focused on commercialising branded women's health and dermatology medicines.

The company operates across three segments: Women's Health, Dermatology and International.

Mayne Pharma operates Manufacturing facilities in Salisbury, South Australia, alongside commercial operations in the United States.

The Business focuses on developing, manufacturing and commercialising pharmaceutical products across selected markets.

The company’s official information highlights its focus on specialty pharmaceutical products and improving access to medicines.

FY2026 Performance

For FY2026, Mayne Pharma reported total Revenue of A$383.7 million, while gross Margin improved compared with the previous year.

The company reported statutory net profit after tax of A$31.2 million following a loss in FY2025.

Underlying EBITDA declined during the period, reflecting changes in operating performance.

Business Development

Women's Health remained an important part of the company’s operations, supported by branded product activities.

The company continued developing its dermatology platform, including expansion of its pharmacy distribution activities.

Future growth depends on product performance, commercial execution and market conditions.

Risks and Considerations

Pharmaceutical businesses face risks including regulatory requirements, competition, pricing pressures and changes in healthcare markets.

Product performance can be affected by market adoption, payer decisions and competitive products.

The company remains exposed to operational and currency considerations across its markets.

Key Insights

Mayne Pharma Group (ASX:MYX) is progressing as a specialty pharmaceutical company with operations across branded medicines, Women's Health and Dermatology. Future performance will depend on product execution, commercial development and broader healthcare market conditions.

FAQs

Q:What is the ASX ticker for Mayne Pharma Group?

A:Mayne Pharma Group trades under (ASX:MYX).

Q:What does Mayne Pharma do?

A:The company develops and commercialises specialty pharmaceutical products.

Q:What are Mayne Pharma’s main segments?

A:The company operates across Women's Health, Dermatology and International segments.

Q:Did Mayne Pharma report a profit in FY2026?

A:Yes. The company reported statutory net profit after tax in FY2026.

Q:What factors are important for Mayne Pharma?

A:Product performance, market access and operational execution are key factors to monitor.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.